ClinicalTrials.gg
RecruitingNCT07857356Updated Nov 12, 2026

Remifentanil Versus Remifentanil-Lidocaine for Tracheal Extubation After Thyroidectomy

A Phase 4 interventional study of remifentanil and Lidocaine %2 ampoule in Tracheal Extubation and Cough, sponsored by Pamukkale University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Pamukkale University · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 8, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Cough with a site in Turkey — 8 open to participants now, 8 under way, none of them phase 3. Cough · Turkey.

Planned enrollment
9th of 11
60 · median 81
Started
2026
with 4 others
Phase 4
Only one
of the 21
Registered
21st of 21
by date

Among the 21 studies in Cough with a site in Turkey, this one is the 9th largest by planned enrollment of the 11 interventional ones that give a count, is one of 5 that started in 2026, is the only one in phase 4, and was the 21st registered.

Cough

429 studies on the registry are indexed under Cough; 68 are open to participants now.

Browse Cough studies →

Open to participants now

8 of the 21 studies in Cough with a site in Turkey are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 45 Cough studies recruiting now, 20 (44%) set no upper age limit and 14 (31%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Cough with a site in Turkey, or all of them as a file.
02

Study summary

This randomized, double-blind clinical trial will compare the effects of remifentanil alone and remifentanil combined with intravenous lidocaine on the quality of tracheal extubation in adult patients undergoing elective thyroidectomy under general anesthesia.

A total of 60 patients will be randomly assigned to two groups. Both groups will receive remifentanil during emergence from anesthesia, while one group will additionally receive intravenous lidocaine before extubation.

The primary outcome will be the incidence of coughing during tracheal extubation. Secondary outcomes will include cough severity, hemodynamic responses, oxygen saturation, airway-related adverse events, postoperative sore throat, hoarseness, postoperative nausea and vomiting, sedation level, and recovery and extubation times.

Read the detailed description

Tracheal extubation may be associated with coughing and hemodynamic responses, which may be undesirable after thyroid surgery. Pharmacological strategies such as remifentanil and intravenous lidocaine may attenuate airway reflexes during emergence from general anesthesia.

This prospective, randomized, double-blind, parallel-group study is designed to evaluate whether the addition of intravenous lidocaine to remifentanil improves the quality of tracheal extubation compared with remifentanil alone in patients undergoing elective thyroidectomy.

Sixty adult patients will be randomly allocated in a 1:1 ratio to receive either remifentanil alone or remifentanil combined with intravenous lidocaine during emergence from anesthesia. Extubation conditions, coughing, hemodynamic variables, respiratory events, recovery characteristics, and postoperative airway-related symptoms will be evaluated.

03

Conditions studied

  • Tracheal Extubation
  • Cough

Browse trials for

Keywords

  • Thyroidectomy
  • Remifentanil
  • Lidocaine
  • Tracheal Extubation
  • Cough
  • Emergence From Anesthesia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 65 years (ASA) physical status I or II Scheduled for elective thyroidectomy under general anesthesia (BMI) \<35 kg/m² Able to provide written

Exclusion criteria

Exclusion Criteria:

  • History of chronic respiratory disease, including asthma or (COPD) Active upper or lower respiratory tract infection Known airway abnormality or anticipated difficult airway Known allergy or to lidocaine Planned postoperative intubation or extubation in the intensive care unit Refusal to participate or withdrawal of consent
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    remifentanil group

    Remifentanil will be administered intravenously during anesthesia maintenance, with the infusion rate titrated according to clinical requirements. Toward the end of surgery, the infusion rate will be reduced to facilitate spontaneous ventilation and tracheal extubation.

    Drug: remifentanil

  • Experimental
    lidocaine-remifentanil

    Participants assigned to this group will receive remifentanil according to the same study protocol and intravenous lidocaine 1.5 mg/kg as a slow bolus over 1-2 minutes during surgical dressing before tracheal extubation.

    Drug: remifentanil · Drug: Lidocaine %2 ampoule

Interventions

  • Remifentanil will be administered intravenously during anesthesia maintenance, with the infusion rate titrated according to clinical requirements. Toward the end of surgery, the infusion rate will be reduced to facilitate spontaneous ventilation and tracheal extubation.

  • DrugLidocaineStudies of LidocaineLidocaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Lidocaine 1.5 mg/kg will be administered intravenously as a slow bolus over 1-2 minutes during surgical dressing before tracheal extubation.

06

What researchers measure

Primary outcomes

  1. Incidence of Cough During Tracheal Extubation

    Cough will be assessed during tracheal extubation. The presence or absence of cough will be recorded for each participant. Cough severity will also be graded using a 4-point cough scale, with higher scores indicating more severe coughing.

    Time frame: During tracheal extubation

Secondary outcomes

  1. Hemodynamic Response During Extubation

    Heart rate will be recorded to evaluate the hemodynamic response to tracheal extubation.

    Time frame: Before extubation, at extubation, and at 1 and 5 minutes after extubation

  2. Incidence of Postoperative Sore Throat

    Postoperative sore throat will be assessed using a 4-point severity scale: 0 = no sore throat, 1 = mild sore throat, 2 = moderate sore throat, and 3 = severe sore throat. Postoperative sore throat will be defined as a score ≥1.

    Time frame: At 1 hours and 24 hours after surgery

  3. Incidence of Postoperative Hoarseness

    Postoperative hoarseness will be assessed using a 4-point severity scale: 0 = no hoarseness, 1 = mild hoarseness, 2 = moderate hoarseness, and 3 = severe hoarseness. Postoperative hoarseness will be defined as a score ≥1.

    Time frame: At 1 hours and 24 hours after surgery

07

Study locations

1 of 1 sites recruiting
  • Pamukkale University Hospitals
    Denizli, Turkey (Türkiye)
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

5 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Nov 2026, 1 month after the start.

Of 20 phase 4 interventional studies under Cough, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 33. This study's planned 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2026
First posted
Oct 5, 2026
StartActual
Oct 1, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 8, 2026
Sites
Pamukkale University Hospitals is now Recruiting
Oct 8, 2026
Registered
First appeared on the registry
Oct 5, 2026
Show all 5 updates
  1. Nov 12, 2026
    Minor edits only
    + 1 other change: arm descriptions
  2. Nov 2, 2026
    Minor edits only
    + 1 other change: date precision
  3. Oct 28, 2026
    Minor edits only
    + 1 other change: verification date
  4. Oct 8, 2026
    Not yet recruiting→Recruiting
    Pamukkale University Hospitals is now Recruiting
  5. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857356
Responsible party
saadet nur yalçın satıcı (Research Assistant, Department of Anesthesiology and Reanimation, Pamukkale University) — Principal investigator
First posted
Oct 5, 2026
Start date
Oct 1, 2026
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Nov 12, 2026

Study contacts

saadet nur YALCIN SATICI
Contact
yalcinsaadetnur@gmail.com
+905066474672
saadet nur YALCIN SATICI
principal investigator · Pamukkale University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion